Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

医学 转移性乳腺癌 内科学 肿瘤科 临床终点 危险系数 人口 乳腺癌 循环肿瘤细胞 癌症 随机对照试验 化疗 转移 置信区间 环境卫生
作者
François‐Clément Bidard,William Jacot,Nicolas Kiavué,Sylvain Dureau,Amir Kadi,William Jacot,Thomas Bachelot,Hugues Bourgeois,Luís Teixeira,Sylvain Ladoire,H. Naman,Florence Dalenc,Joseph Gligorov,Marc Espié,George Emile,Jean‐Marc Ferrero,Thomas Bachelot,Sophie Frank,Luc Cabel,Véronique Dièras,Laure Cayrefourcq,Cécile Simondi,Frédérique Berger,Catherine Alix‐Panabières,Jean‐Yves Pierga
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (1): 34-34 被引量:112
标识
DOI:10.1001/jamaoncol.2020.5660
摘要

Importance

The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) is a strong adverse prognostic factor for overall survival and progression-free survival (PFS).

Objective

To compare the efficacy of a clinician-driven treatment choice vs a CTC-driven choice for first-line treatment.

Interventions

In the CTC arm, patients received chemotherapy or endocrine therapy according to the CTC count (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL), whereas in the control arm, the choice was left to the investigator.

Design, Setting, and Participants

In the STIC CTC randomized, open-label, noninferiority phase 3 trial, participants were randomized to a clinician-driven choice of first-line treatment or a CTC count–driven first-line treatment choice. Eligible participants were premenopausal and postmenopausal women 18 years or older diagnosed with hormone receptor–positive, ERBB2-negative metastatic breast cancer. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019.

Main Outcome and Measures

The primary end point was the investigator-assessed PFS in the per-protocol population, with a noninferiority margin of 1.25 for the 90% CI of the hazard ratio.

Results

Among the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years [64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm]; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median PFS was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09).

Conclusions and Relevance

This randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor–positive, ERBB2-negative metastatic breast cancer.

Trial Registration

ClinicalTrials.gov Identifier:NCT01710605
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhuangzhu发布了新的文献求助10
刚刚
1秒前
1秒前
科研通AI2S应助曲初雪采纳,获得30
2秒前
桐桐应助芋泥啵啵采纳,获得10
2秒前
2秒前
小王同学搞学术完成签到,获得积分10
3秒前
黙宇循光发布了新的文献求助10
3秒前
1234完成签到,获得积分10
4秒前
祈祈发布了新的文献求助10
5秒前
6秒前
perry4rosa完成签到,获得积分0
6秒前
march完成签到,获得积分10
6秒前
ZXH发布了新的文献求助10
6秒前
顺顺利利发布了新的文献求助10
7秒前
名金学南完成签到,获得积分10
8秒前
学术小白发布了新的文献求助10
12秒前
uie完成签到,获得积分10
13秒前
13秒前
14秒前
蓝色花生豆完成签到,获得积分10
15秒前
16秒前
Ahha发布了新的文献求助10
18秒前
18秒前
danxue完成签到,获得积分10
18秒前
19秒前
完美世界应助科研通管家采纳,获得10
20秒前
甜甜玫瑰应助科研通管家采纳,获得10
20秒前
上官若男应助科研通管家采纳,获得10
20秒前
SciGPT应助科研通管家采纳,获得10
20秒前
情怀应助科研通管家采纳,获得30
20秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
甜甜玫瑰应助科研通管家采纳,获得10
20秒前
酷波er应助科研通管家采纳,获得10
21秒前
隐形曼青应助科研通管家采纳,获得10
21秒前
传奇3应助科研通管家采纳,获得10
21秒前
Singularity应助科研通管家采纳,获得20
21秒前
21秒前
21秒前
汉堡包应助科研通管家采纳,获得10
21秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138888
求助须知:如何正确求助?哪些是违规求助? 2789815
关于积分的说明 7792820
捐赠科研通 2446185
什么是DOI,文献DOI怎么找? 1300930
科研通“疑难数据库(出版商)”最低求助积分说明 626066
版权声明 601079